TIMM22

Across TCGA pan-cancer cohorts, TIMM22 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TIMM22 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TIMM22 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TIMM22 expression acts as an unfavorable survival marker, although some lineages such as LSCC and COAD show a favorable association.

LSCC, COAD, and PDAC are the cancer types where TIMM22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.936	0.680	.004	19	view →
COAD	DFS	Tertile	III,IV	1.000	0.838	.027	18	view →
PDAC	OS	Tertile	IV	0.973	0.443	.024	9	view →
CCRCC	DFS	Tertile	II,III,IV	0.450	0.870	.005	8	view →
UCEC	DFS	Median	All	0.786	0.933	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TIMM22–LSCC (OS)

Open the LSCC breakdown →